This article was originally published in The Gray Sheet
AbioCor replacement heart will be implanted in five patients to begin initial clinical trial of the destination therapy device, firm announces Jan 30. Endpoints are patient survival and quality of life (1"The Gray Sheet" Jan. 15, 2001, p. 3). While FDA granted an IDE for the implantation, the agency also has required Abiomed to respond to a series of questions within 45 days. Implantation will begin as soon as end-stage heart failure patients can be identified who are at risk for imminent death, are not transplantable and cannot be helped by other therapies
You may also be interested in...
Abiomed may be able to leverage its strength in the capital markets - specifically, an enhanced cash position resulting from a $95 mil. secondary offering last March - to undercut a previously announced all-stock bid by Thoratec for ventricular assist device developer Thermo CardioSystems.
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.